307 related articles for article (PubMed ID: 24662916)
1. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.
Lennon FE; Mirzapoiazova T; Mambetsariev B; Poroyko VA; Salgia R; Moss J; Singleton PA
PLoS One; 2014; 9(3):e91577. PubMed ID: 24662916
[TBL] [Abstract][Full Text] [Related]
2. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.
Mathew B; Lennon FE; Siegler J; Mirzapoiazova T; Mambetsariev N; Sammani S; Gerhold LM; LaRiviere PJ; Chen CT; Garcia JG; Salgia R; Moss J; Singleton PA
Anesth Analg; 2011 Mar; 112(3):558-67. PubMed ID: 21156980
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.
Lennon FE; Mirzapoiazova T; Mambetsariev B; Salgia R; Moss J; Singleton PA
Anesthesiology; 2012 Apr; 116(4):857-67. PubMed ID: 22343475
[TBL] [Abstract][Full Text] [Related]
4. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
Fujioka N; Nguyen J; Chen C; Li Y; Pasrija T; Niehans G; Johnson KN; Gupta V; Kratzke RA; Gupta K
Anesth Analg; 2011 Dec; 113(6):1353-64. PubMed ID: 22003224
[TBL] [Abstract][Full Text] [Related]
5. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
6. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
[TBL] [Abstract][Full Text] [Related]
8. YXQ-EQ Induces Apoptosis and Inhibits Signaling Pathways Important for Metastasis in Non-Small Cell Lung Carcinoma Cells.
Yan X; Shen H; Jiang H; Hu D; Wang J; Wu X
Cell Physiol Biochem; 2018; 49(3):911-919. PubMed ID: 30184531
[TBL] [Abstract][Full Text] [Related]
9. Blocking M2 muscarinic receptor signaling inhibits tumor growth and reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC).
Zhao Q; Gu X; Zhang C; Lu Q; Chen H; Xu L
Cancer Biol Ther; 2015; 16(4):634-43. PubMed ID: 25778781
[TBL] [Abstract][Full Text] [Related]
10. Snail regulated by PKC/GSK-3β pathway is crucial for EGF-induced epithelial-mesenchymal transition (EMT) of cancer cells.
Liu ZC; Chen XH; Song HX; Wang HS; Zhang G; Wang H; Chen DY; Fang R; Liu H; Cai SH; Du J
Cell Tissue Res; 2014 Nov; 358(2):491-502. PubMed ID: 25124796
[TBL] [Abstract][Full Text] [Related]
11. Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated Epithelial-to-Mesenchymal Transition.
Hsieh YS; Liao CH; Chen WS; Pai JT; Weng MS
J Cell Biochem; 2017 Dec; 118(12):4639-4651. PubMed ID: 28485480
[TBL] [Abstract][Full Text] [Related]
12. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
Cai WK; Hu J; Li T; Meng JR; Ma X; Yin SJ; Zhao CH; He GH; Xu GL
Eur J Cancer; 2014 Apr; 50(6):1195-206. PubMed ID: 24447834
[TBL] [Abstract][Full Text] [Related]
13. MOR promotes epithelial-mesenchymal transition and proliferation via PI3K/AKT signaling pathway in human colorectal cancer.
Gao L; Yang L; He Y; Liu Y; Xu P; Zhang J; Dai S; Luo X; Sun Z
Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 55(1):72-80. PubMed ID: 35983971
[TBL] [Abstract][Full Text] [Related]
14. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
15. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CXCR4 regulates epithelial mesenchymal transition of NSCLC via the Hippo-YAP signaling pathway.
Zheng CH; Chen XM; Zhang FB; Zhao C; Tu SS
Cell Biol Int; 2018 Sep; 42(10):1386-1394. PubMed ID: 29972256
[TBL] [Abstract][Full Text] [Related]
17. Src promotes EGF-induced epithelial-to-mesenchymal transition and migration in gastric cancer cells by upregulating ZEB1 and ZEB2 through AKT.
Zhao L; Li X; Song N; Li A; Hou K; Qu X; Che X; Liu Y
Cell Biol Int; 2018 Mar; 42(3):294-302. PubMed ID: 29052277
[TBL] [Abstract][Full Text] [Related]
18. ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.
Buonato JM; Lazzara MJ
Cancer Res; 2014 Jan; 74(1):309-19. PubMed ID: 24108744
[TBL] [Abstract][Full Text] [Related]
19. Downregulating CD26/DPPIV by apigenin modulates the interplay between Akt and Snail/Slug signaling to restrain metastasis of lung cancer with multiple EGFR statuses.
Chang JH; Cheng CW; Yang YC; Chen WS; Hung WY; Chow JM; Chen PS; Hsiao M; Lee WJ; Chien MH
J Exp Clin Cancer Res; 2018 Aug; 37(1):199. PubMed ID: 30134935
[TBL] [Abstract][Full Text] [Related]
20. Ascofuranone inhibits epidermal growth factor-induced cell migration by blocking epithelial-mesenchymal transition in lung cancer cells.
Kim HW; Jeong YJ; Hwang SK; Park YY; Choi YH; Kim CH; Magae J; Chang YC
Eur J Pharmacol; 2020 Aug; 880():173199. PubMed ID: 32439259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
